Biopharmaceuticals Contract Manufacturing Market Expansion Continues, with Forecast Valuation of $33.99 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Biopharmaceuticals Contract Manufacturing Market Size By 2025?
The market size for contract manufacturing in the biopharmaceutical sector has seen significant growth over the past few years. It is projected to expand from a valuation of $20.13 billion in 2024 to an approximate worth of $22.22 billion in 2025, experiencing a compound annual growth rate (CAGR) of 10.4%. Factors contributing to the remarkable growth observed in the historical period include heightened development of biopharmaceuticals, cost-effectiveness alongside risk reduction, an increasing lineup of biologics, the internationalization of the biopharmaceutical industry, and adaptable manufacturing solutions.

How Big Is the Biopharmaceuticals Contract Manufacturing Market Size Expected to Grow by 2029?
The market size of biopharmaceuticals contract manufacturing is anticipated to surge remarkably in the upcoming years, reaching a value of $33.99 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 11.2%. The substantial growth predicted for this period can be attributed to several factors, including the increasing trend towards outsourcing, major developments in biosimilars, lessened time-to-market demands, expansion on a global scale, and a more intense concentration on specialized services. Key trends to keep an eye on during the forecast period consist of enhanced technological incorporation, expansion of outsourcing beyond large molecules, adoption of advanced production technologies, emphasis on quality and compliance, and the burgeoning field of biosimilars manufacturing.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Which Key Market Drivers Powering Biopharmaceuticals Contract Manufacturing Market Expansion and Growth?
The surge in the need for personalized healthcare is projected to push the growth of the biopharmaceutical contract manufacturing market forwards. Personalized treatments, which factor in various traits unique to the patient such as genetics, environment, and lifestyle, are rising in demand due to their potential to improve the effectiveness of treatments and their outcomes. This need is fueled by progress in genomics, patient empowerment, and enhanced treatment outcomes. Habilitated to adapt to unique demands, contract manufacturers can construct production procedures to conform to the precise requirements of these individualized therapies, accommodating smaller batches and distinct formulations. For example, the FDA in February 2024 approved 16 new therapies for patients suffering from rare diseases, according to the US-based non-profit organization, the Personalized Medicine Coalition. This was a significant increase from six approvals in 2022. Consequently, the escalating demand for personalized medicinal treatments is propelling the growth of the biopharmaceutical contract manufacturing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10181&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Biopharmaceuticals Contract Manufacturing Market?
The trend of product innovation is gathering pace in the biopharmaceuticals contract manufacturing market. To maintain their standing, many key players in this industry are focusing on introducing novel products. For example, in February 2023, Thermo Fisher Scientific, a biotechnology research establishment based in the US, joined hands with Elektrofi, a US-based biotech company known for pioneering drug formulation and delivery innovations. Their strategic contract manufacturing collaboration was aimed at facilitating the commercial production of Elektrofi's trailblazing ultra-high concentration subcutaneous products. Elektrofi's unique microparticle technology makes it possible to inject small volumes of biologics, such as monoclonal antibodies and therapeutic proteins, as well as other significant large-molecule medications. Elektrofi's platform technology helps patients to administer medicines by themselves at home, bypassing the challenges associated with handling biologic-based medications in a hospital environment.

What Are the Emerging Segments in the Biopharmaceuticals Contract Manufacturing Market?
The biopharmaceuticals contract manufacturing market covered in this report is segmented -

1) By Product: Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, And Molecular Therapy, Biosimilars
2) By Source: Mammalian, Non-mammalian
3) By Service: Process Development, Fill And Finish Operations, Analytical And QC studies, Packaging
4) By Application: Clinical, Commercial

Subsegments:
1) By Biologics: Enzymes, Hormones, Antibodies
2) By Monoclonal Antibodies (MABs): Human MABs, Chimeric MABs, Murine MABs
3) By Recombinant Proteins: Insulin, Growth Factors, Cytokines
4) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines
5) By Antisense, RNAi, And Molecular Therapy: Antisense Oligonucleotides, RNA Interference Products, Gene Therapies
6) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulin, Biosimilar Growth Hormones

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10181&type=smp

Who Are the Global Leaders in the Biopharmaceuticals Contract Manufacturing Market?
Major companies operating in the biopharmaceuticals contract manufacturing market include Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG, Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC, Baxter International Inc., Becton dic*kinson and Company, Polyphor Ltd., Patheon Inc., Alcami Corporation

Which are the Top Profitable Regional Markets for the Biopharmaceuticals Contract Manufacturing Industry?
North America was the largest region in the biopharmaceutical contract manufacturing market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global biopharmaceuticals contract manufacturing market forecast period. The regions covered in the biopharmaceuticals contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10181

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.